Mount Sinai, Pfizer Renew Research Collaboration, Building on Strong Foundation
The Icahn School of Medicine at Mount Sinai and Pfizer Inc.’s Centers for Therapeutic Innovation (CTI) recently announced the renewal of an agreement designed to identify and advance new drug candidates linked to major diseases, such as cancer, rheumatoid arthritis, Crohn’s disease, colitis, heart failure, Alzheimer’s disease, and cystic fibrosis.
In 2010, Mount Sinai became one of the first academic medical centers to enter into a collaboration with CTI, a Pfizer research group with the aim of speeding novel drugs toward approval for use in the clinic. The collaboration allows Mount Sinai investigators to submit research proposals to CTI, and for CTI to provide funding and drug development expertise, which can facilitate the development of new therapies. To date, five Mount Sinai projects have been funded through this process, focusing mainly in the areas of diabetes, autoimmune disease and cancer.
Project proposals are chosen through a rigorous vetting process by a steering committee composed of leading Pfizer and Mount Sinai scientists. Funded projects must have the strong potential to address an unmet medical need. Resulting research collaborations complement the biological expertise at Mount Sinai with Pfizer’s drug discovery and development capabilities, including the ability to create antibodies and small-molecules.
“Best–in-class translational research rarely occurs in a vacuum. Mount Sinai is dedicated to bringing therapeutics from the bench to the bedside, to improve health outcomes. Capitalizing on the synergies between industry and academic capabilities brings us closer to this goal,” said Erik Lium, PhD, Senior Vice President of Mount Sinai Innovation Partners (MSIP), the technology development and commercialization arm of Mount Sinai.
According to CTI’s Chief Scientific Officer, Anthony J. Coyle, PhD, “CTI and Mount Sinai have a long-standing and exceptional track record of research collaboration aimed at bringing early-stage medical discoveries towards the clinic. This renewed commitment will further enhance our alliance.”
MSIP facilitates the real-world application and commercialization of Mount Sinai discoveries and the development of research partnerships with industry. MSIP is responsible for the full spectrum of commercialization activities required to bring the Icahn School of Medicine’s inventions to life. These activities include evaluating, patenting, marketing, and licensing new technologies, while also engaging commercial and non-profit relationships for sponsored research, material transfer, and confidentiality. For more information, visit www.ip.mountsinai.org.
About the Mount Sinai Health System
The Mount Sinai Health System is New York City's largest integrated delivery system encompassing (with the addition of South Nassau Communities Hospital) eight hospital campuses, a leading medical school, and a vast network of ambulatory practices throughout the greater New York region. Mount Sinai's vision is to produce the safest care, the highest quality, the highest satisfaction, the best access and the best value of any health system in the nation. The Health System includes approximately 7,480 primary and specialty care physicians; 11 joint-venture ambulatory surgery centers; more than 410 ambulatory practices throughout the five boroughs of New York City, Westchester, Long Island, and Florida; and 31 affiliated community health centers. The Icahn School of Medicine is one of three medical schools that have earned distinction by multiple indicators: ranked in the top 20 by U.S. News & World Report's "Best Medical Schools", aligned with a U.S. News & World Report's "Honor Roll" Hospital, No. 12 in the nation for National Institutes of Health funding, and among the top 10 most innovative research institutions as ranked by the journal Nature in its Nature Innovation Index. This reflects a special level of excellence in education, clinical practice, and research. The Mount Sinai Hospital is ranked No. 18 on U.S. News & World Report's "Honor Roll" of top U.S. hospitals; it is one of the nation's top 20 hospitals in Cardiology/Heart Surgery, Gastroenterology/GI Surgery, Geriatrics, Nephrology, and Neurology/Neurosurgery, and in the top 50 in six other specialties in the 2018-2019 "Best Hospitals" issue. Mount Sinai's Kravis Children's Hospital also is ranked nationally in five out of ten pediatric specialties by U.S. News & World Report. The New York Eye and Ear Infirmary of Mount Sinai is ranked 11th nationally for Ophthalmology and 44th for Ear, Nose, and Throat. Mount Sinai Beth Israel, Mount Sinai St. Luke's, Mount Sinai West, and South Nassau Communities Hospital are ranked regionally.